Brain Region-specific Lipid Alterations in the PLB4 HBACE1 Knock-in Mouse Model of Alzheimer's Disease

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2020 Sep 2

PMID 32867761

Citations 5

Authors

Madhurima Dey

Frank J Gunn-Moore

Bettina Platt

Terry K Smith

Affiliations

Soon will be listed here.

Abstract

Background: Lipid dysregulation is associated with several key characteristics of Alzheimer's disease (AD), including amyloid-β and tau neuropathology, neurodegeneration, glucose hypometabolism, as well as synaptic and mitochondrial dysfunction. The β-site amyloid precursor protein cleavage enzyme 1 (BACE1) is associated with increased amyloidogenesis, and has been affiliated with diabetes via its role in metabolic regulation.

Methods: The research presented herein investigates the role of hBACE1 in lipid metabolism and whether specific brain regions show increased vulnerability to lipid dysregulation. By utilising advanced mass spectrometry techniques, a comprehensive, quantitative lipidomics analysis was performed to investigate the phospholipid, sterol, and fatty acid profiles of the brain from the well-known PLB4 hBACE1 knock-in mouse model of AD, which also shows a diabetic phenotype, to provide insight into regional alterations in lipid metabolism.

Results: Results show extensive region - specific lipid alterations in the PLB4 brain compared to the wild-type, with decreases in the phosphatidylethanolamine content of the cortex and triacylglycerol content of the hippocampus and hypothalamus, but increases in the phosphatidylcholine, phosphatidylinositol, and diacylglycerol content of the hippocampus. Several sterol and fatty acids were also specifically decreased in the PLB4 hippocampus.

Conclusion: Collectively, the lipid alterations observed in the PLB4 hBACE1 knock-in AD mouse model highlights the regional vulnerability of the brain, in particular the hippocampus and hypothalamus, to lipid dysregulation, hence supports the premise that metabolic abnormalities have a central role in both AD and diabetes.

Citing Articles

Cortical lipid metabolic pathway alteration of early Alzheimer's disease and candidate drugs screen.

Wang L, Qu F, Yu X, Yang S, Zhao B, Chen Y Eur J Med Res. 2024; 29(1):199.

PMID: 38528586 PMC: 10962147. DOI: 10.1186/s40001-024-01730-w.

Brain areas lipidomics in female transgenic mouse model of Alzheimer's disease.

Ferre-Gonzalez L, Balaguer A, Roca M, Ftara A, Lloret A, Chafer-Pericas C Sci Rep. 2024; 14(1):870.

PMID: 38195731 PMC: 10776612. DOI: 10.1038/s41598-024-51463-3.

Sex Modifies the Impact of Type 2 Diabetes Mellitus on the Murine Whole Brain Metabolome.

Norman J, Nuthikattu S, Milenkovic D, Villablanca A Metabolites. 2023; 13(9).

PMID: 37755291 PMC: 10536706. DOI: 10.3390/metabo13091012.

Exploring the Role of Lipid-Binding Proteins and Oxidative Stress in Neurodegenerative Disorders: A Focus on the Neuroprotective Effects of Nutraceutical Supplementation and Physical Exercise.

Scarfo G, Piccarducci R, Daniele S, Franzoni F, Martini C Antioxidants (Basel). 2022; 11(11).

PMID: 36358488 PMC: 9686611. DOI: 10.3390/antiox11112116.

Synapses, Microglia, and Lipids in Alzheimer's Disease.

Paasila P, Aramideh J, Sutherland G, Graeber M Front Neurosci. 2022; 15:778822.

PMID: 35095394 PMC: 8789683. DOI: 10.3389/fnins.2021.778822.

References

Plucinska K, Crouch B, Koss D, Robinson L, Siebrecht M, Riedel G . Knock-in of human BACE1 cleaves murine APP and reiterates Alzheimer-like phenotypes. J Neurosci. 2014; 34(32):10710-28. PMC: 4122804. DOI: 10.1523/JNEUROSCI.0433-14.2014. View

Vassar R, Bennett B, Kahn S, Mendiaz E, Denis P, Teplow D . Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286(5440):735-41. DOI: 10.1126/science.286.5440.735. View

de Chaves E, Rusinol A, Vance D, Campenot R, Vance J . Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. J Biol Chem. 1998; 272(49):30766-73. DOI: 10.1074/jbc.272.49.30766. View

Holcomb L, Gordon M, McGowan E, Yu X, Benkovic S, Jantzen P . Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998; 4(1):97-100. DOI: 10.1038/nm0198-097. View

Wood P, Medicherla S, Sheikh N, Terry B, Phillipps A, Kaye J . Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer's Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer's Disease. J Alzheimers Dis. 2015; 48(2):537-46. PMC: 4713833. DOI: 10.3233/JAD-150336. View

Wood P, Locke V, Herling P, Passaro A, Vigna G, Volpato S . Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD). BBA Clin. 2016; 5:25-8. PMC: 4802395. DOI: 10.1016/j.bbacli.2015.11.004. View

Hu X, Fan Q, Hou H, Yan R . Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling. J Neurochem. 2015; 136(2):234-49. PMC: 4833723. DOI: 10.1111/jnc.13395. View

Saura J, Petegnief V, Wu X, Liang Y, Paul S . Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. J Neurochem. 2003; 85(6):1455-67. DOI: 10.1046/j.1471-4159.2003.01788.x. View

Wood P, Barnette B, Kaye J, Quinn J, Woltjer R . Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects. Acta Neuropsychiatr. 2015; 27(5):270-8. DOI: 10.1017/neu.2015.18. View

10.

Houlden H, Crook R, Backhovens H, Prihar G, Baker M, Hutton M . ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. Am J Med Genet. 1998; 81(1):117-21. DOI: 10.1002/(sici)1096-8628(19980207)81:1<117::aid-ajmg19>3.0.co;2-m. View

11.

Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

12.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

13.

Breunig J, Silbereis J, Vaccarino F, Sestan N, Rakic P . Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. Proc Natl Acad Sci U S A. 2007; 104(51):20558-63. PMC: 2154470. DOI: 10.1073/pnas.0710156104. View

14.

Wenk M . The emerging field of lipidomics. Nat Rev Drug Discov. 2005; 4(7):594-610. DOI: 10.1038/nrd1776. View

15.

Frere S, Chang-Ileto B, Paolo G . Role of phosphoinositides at the neuronal synapse. Subcell Biochem. 2012; 59:131-75. PMC: 3543677. DOI: 10.1007/978-94-007-3015-1_5. View

16.

Bejanin A, Schonhaut D, La Joie R, Kramer J, Baker S, Sosa N . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017; 140(12):3286-3300. PMC: 5841139. DOI: 10.1093/brain/awx243. View

17.

Linetti A, Fratangeli A, Taverna E, Valnegri P, Francolini M, Cappello V . Cholesterol reduction impairs exocytosis of synaptic vesicles. J Cell Sci. 2010; 123(Pt 4):595-605. DOI: 10.1242/jcs.060681. View

18.

Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L . Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. Alzheimers Dement. 2016; 13(2):140-151. DOI: 10.1016/j.jalz.2016.08.003. View

19.

Mahley R . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240(4852):622-30. DOI: 10.1126/science.3283935. View

20.

Hamilton J, Hillard C, Spector A, Watkins P . Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders. J Mol Neurosci. 2007; 33(1):2-11. DOI: 10.1007/s12031-007-0060-1. View